Spectranetics Announces First Quarter 2017 Conference Call
April 07 2017 - 4:30PM
The Spectranetics Corporation (NASDAQ:SPNC), today announced that
the Company will release first quarter 2017 financial results on
Thursday, April 27, 2017. Company management will host a conference
call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time)
to discuss the results. The dial-in for the conference call is
(877) 561-2747 for domestic callers or (973) 409-9689 for
international callers, and the Conference ID is 3440087.
There will also be a live webcast on the investor
relations section of the Company’s website at
www.spectranetics.com, which will be available on the Company’s
website for 14 days following the completion of the call.
About Spectranetics
The Spectranetics Corporation develops,
manufactures, markets and distributes medical devices used in
minimally invasive procedures within the cardiovascular system. The
Company's products are available in over 65 countries and are used
to treat arterial blockages in the heart and legs and in the
removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products
include a range of laser catheters for ablation of blockages in
arteries above and below the knee, the AngioSculpt scoring balloon
used in both peripheral and coronary procedures, and the Stellarex
drug-coated balloon peripheral angioplasty platform, which received
European CE mark approval in December 2014. The Company also
markets support catheters to facilitate crossing of peripheral and
coronary arterial blockages, and retrograde access and guidewire
retrieval devices used in the treatment of peripheral arterial
blockages, including chronic total occlusions. The Company markets
aspiration and cardiac laser catheters to treat blockages in the
heart.
The Lead Management (LM) product line includes
excimer laser sheaths, dilator sheaths, mechanical sheaths and
accessories for the removal of pacemaker and defibrillator cardiac
leads, including the Bridge™ Occlusion Balloon.
For more information, visit
www.spectranetics.com.
Safe Harbor Statement
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. You can identify these
statements because they do not relate strictly to historical or
current facts. Such statements may include words such as
“anticipate,” “will,” “estimate,” “expect,” “look forward,”
“strive,” “project,” “intend,” “should,” “plan,” “believe,” “hope,”
“see,” “enable,” “potential,” and other words and terms of similar
meaning in connection with any discussion of, among other things,
future operating or financial performance, strategic initiatives
and business strategies, clinical trials and regulatory approvals,
regulatory or competitive environments, outcome of litigation, our
intellectual property and product development. These
forward-looking statements include, but are not limited to,
statements regarding our competitive position, product innovation
and development, and commercialization schedule, expectation of
continued growth and the reasons for that growth, growth rates,
strength, integration and product launches, regulatory approvals,
and 2017 outlook and projected results including projected revenue
and expenses, gross margin, net loss and loss per share. Such
statements are based on current assumptions that involve risks and
uncertainties that could cause actual outcomes and results to
differ materially. You are cautioned not to place undue reliance on
these forward-looking statements and to note they speak only as of
the date of this release. These risks and uncertainties may include
financial results differing from guidance; our need to comply with
complex and evolving laws and regulations; intense and increasing
competition and consolidation in our industry; the impact of rapid
technological change; slower revenue growth and continued losses;
the inaccuracy of our assumptions regarding AngioScore and
Stellarex; market acceptance of our technology and products; our
inability to manage growth; increased pressure on expense levels
resulting from expanded sales, marketing, product development and
clinical activities; uncertain success of our strategic direction;
dependence on new product development and successful
commercialization of new products; loss of key personnel; uncertain
success of or delays in our clinical trials; costs of and adverse
results in any ongoing or future legal proceedings; adverse impact
to our business from healthcare reform and related legislation and
regulations, including changes in reimbursements and the impact of
fraud and abuse and information privacy laws and regulations;
adverse conditions in the general domestic and global economic
markets and volatility and disruption of the credit markets or
other factors that prevent us from obtaining funding; our inability
to protect our intellectual property and intellectual property
claims of third parties; availability of inventory and components
from suppliers, including sole source suppliers; adverse outcome of
FDA inspections, including FDA warning letters and any remediation
efforts; the receipt of FDA clearance and other regulatory
approvals to market new products or applications and the timeliness
of any clearance and approvals; product defects or recalls and
product liability claims; cybersecurity breaches; interruptions of
our manufacturing operations and other events that affect our
ability to manufacture sufficient volumes to fulfill customer
demand; our dependence on third party vendors, suppliers,
consultants and physicians; risks associated with international
operations, including international sales using distributors and
the impact of “Brexit” on our European sales and operations; risks
associated with any future acquisitions; our ability to use net
operating loss carryovers and potential impairment charges; lack of
cash necessary to satisfy our cash obligations under our
outstanding 2.625% Convertible Senior Notes due 2034 and our term
loan and revolving loan facilities; our debt adversely affecting
our financial health and preventing us from fulfilling our debt
service and other obligations; and share price volatility due to
the initiation or cessation of coverage, or changes in ratings, by
securities analysts. For a further list and description of such
risks and uncertainties that could cause our actual results,
performance or achievements to materially differ from any
anticipated results, performance or achievements, please see our
previously filed SEC reports, including those risks set forth in
our 2016 Annual Report on Form 10-K. We disclaim any intention or
obligation to update or revise any financial or other projections
or other forward-looking statements, whether because of new
information, future events or otherwise.
Investor Relations Contacts
Zach Stassen
Vice President, Finance
zach.stassen@spnc.com
(719) 447-2292
Michaella Gallina
Director of Investor Relations
michaella.gallina@spnc.com
(719) 447-2417
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Apr 2023 to Apr 2024